Home › NDC Lookup › RxCUI directory › RxCUI 1535451

Dextroamphetamine sulfate 15 MG Oral Tablet [Zenzedi] — RxCUI 1535451

Name: Dextroamphetamine sulfate 15 MG Oral Tablet [Zenzedi] (RxCUI 1535451)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 1535451 Semantic branded drug · SBD ● Current RxNorm concept 7 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1535451

Official nameDextroamphetamine sulfate 15 MG Oral Tablet [Zenzedi]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asZenzedi 15 MG Oral Tablet

FDA products mapped7

Package NDCs mapped7

Reported Medicaid activity (SDUD)192 prescriptions · 5 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Dextroamphetamine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

It sounds counterintuitive, but stimulants actually calm things down for many people with ADHD. Dextroamphetamine boosts dopamine and norepinephrine — two brain chemicals involved...
What exactly does dextroamphetamine do, and why does a stimulant help with ADHD?
The most common ones are decreased appetite, trouble sleeping, and headache — and decreased appetite is very common, especially early on. Taking doses too late in the day tends to...
What are the most common side effects I should expect?

📖 Read our full Dextroamphetamine guide →

🕸️ Concept Web — How Dextroamphetamine sulfate 15 MG Oral Tablet [Zen... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Dextroamphetamine sulfate 15 MG Oral Tablet [Zenzedi] RxCUI 1535451 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Dextroamphetamine 3288 IN
- Dextroamphetamine sulfate 3287 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Zenzedi 1425332 BN
Dose forms 13

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Dextroamphetamine Oral Tablet 371753 SCDF
- Dextroamphetamine sulfate Oral Tablet 2647496 SCDFP
- Dextroamphetamine Oral Product 1154565 SCDG
- Dextroamphetamine Pill 1154566 SCDG
- Dextroamphetamine sulfate Oral Product 2662479 SCDGP
- Dextroamphetamine sulfate Pill 2661847 SCDGP
- Dextroamphetamine Oral Tablet [Zenzedi] 1425334 SBDF
- Dextroamphetamine sulfate Oral Tablet [Zenzedi] 2656743 SBDFP
- +5 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Dextroamphetamine sulfate 15 MG Oral Tablet 884684 SCD
- Dextroamphetamine sulfate 15 MG 884531 SCDC
- Dextroamphetamine sulfate 15 MG [Zenzedi] 1535450 SBDC

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Dextroamphetamine sulfate 15 MG Oral Tablet SCD · 884684
Dextroamphetamine sulfate 15 MG SCDC · 884531
Dextroamphetamine Oral Tablet SCDF · 371753
Dextroamphetamine sulfate Oral Tablet SCDFP · 2647496
Dextroamphetamine Oral Product SCDG · 1154565
Dextroamphetamine Pill SCDG · 1154566
Dextroamphetamine sulfate Oral Product SCDGP · 2662479
Dextroamphetamine sulfate Pill SCDGP · 2661847

Brand-Name Concepts

Dextroamphetamine sulfate 15 MG [Zenzedi] SBDC · 1535450
Dextroamphetamine Oral Tablet [Zenzedi] SBDF · 1425334
Dextroamphetamine sulfate Oral Tablet [Zenzedi] SBDFP · 2656743
Zenzedi Oral Product SBDG · 1425335
Zenzedi Pill SBDG · 1425336
Zenzedi BN · 1425332

📦 FDA Products & Package NDCs

7 products · 7 package NDCs

7 package NDCs map to RxCUI 1535451 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
24338-0850-03	30 TABLET in 1 BOTTLE (24338-850-03)	Zenzedi	Azurity Pharmaceuticals, Inc.	2021-03-10
24338-0851-03	30 TABLET in 1 BOTTLE (24338-851-03)	Zenzedi	Azurity Pharmaceuticals, Inc.	2021-03-12
24338-0852-03	30 TABLET in 1 BOTTLE (24338-852-03)	Zenzedi	Azurity Pharmaceuticals, Inc.	2021-03-12
24338-0853-03	30 TABLET in 1 BOTTLE (24338-853-03)	Zenzedi	Azurity Pharmaceuticals, Inc.	2021-03-12
24338-0854-03	30 TABLET in 1 BOTTLE (24338-854-03)	Zenzedi	Azurity Pharmaceuticals, Inc.	2021-03-12
24338-0855-03	30 TABLET in 1 BOTTLE (24338-855-03)	Zenzedi	Azurity Pharmaceuticals, Inc.	2021-03-12
24338-0856-03	30 TABLET in 1 BOTTLE (24338-856-03)	Zenzedi	Azurity Pharmaceuticals, Inc.	2021-03-12

Observed labelers: Azurity Pharmaceuticals, Inc. (7) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.